CO6440584A2 - Compuestos diamida que tienen actividad como antagonistas de los receptores muscarínicos y como agonistas de los receptores adrenérgicos beta 2 - Google Patents

Compuestos diamida que tienen actividad como antagonistas de los receptores muscarínicos y como agonistas de los receptores adrenérgicos beta 2

Info

Publication number
CO6440584A2
CO6440584A2 CO11139777A CO11139777A CO6440584A2 CO 6440584 A2 CO6440584 A2 CO 6440584A2 CO 11139777 A CO11139777 A CO 11139777A CO 11139777 A CO11139777 A CO 11139777A CO 6440584 A2 CO6440584 A2 CO 6440584A2
Authority
CO
Colombia
Prior art keywords
receivers
compounds
muscarinic
agonists
antagonists
Prior art date
Application number
CO11139777A
Other languages
English (en)
Inventor
Adam Hughes
Daniel Byun
Yan Chen
Melissa Fleury
John R Jacobsen
Eric L Stangeland
Richard D Wilson
Rose Yen
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42272140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6440584(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of CO6440584A2 publication Critical patent/CO6440584A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Esta invención se refiere a un compuesto de fórmula I:o una sal farmacéuticamente aceptable del mismo. Dichos compuestos poseen actividad tanto como antagonistas de los receptores muscarínicos cuanto como agonistas de los receptores adrenérgicos ß2. La invención también se refiere a composiciones farmacéuticas que comprenden dichos compuestos, procesos e intermediarios para preparar dichos compuestos, y métodos para usar dichos compuestos como agentes broncodilatadores para tratar trastornos pulmonares.
CO11139777A 2009-04-23 2011-10-19 Compuestos diamida que tienen actividad como antagonistas de los receptores muscarínicos y como agonistas de los receptores adrenérgicos beta 2 CO6440584A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17203909P 2009-04-23 2009-04-23

Publications (1)

Publication Number Publication Date
CO6440584A2 true CO6440584A2 (es) 2012-05-15

Family

ID=42272140

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11139777A CO6440584A2 (es) 2009-04-23 2011-10-19 Compuestos diamida que tienen actividad como antagonistas de los receptores muscarínicos y como agonistas de los receptores adrenérgicos beta 2

Country Status (32)

Country Link
US (14) US8138345B2 (es)
EP (3) EP3210981B1 (es)
JP (3) JP5671006B2 (es)
KR (1) KR101769061B1 (es)
CN (2) CN102405218B (es)
AR (1) AR076412A1 (es)
AU (1) AU2010239522B2 (es)
BR (1) BRPI1014877B8 (es)
CA (1) CA2758505C (es)
CL (1) CL2011002637A1 (es)
CO (1) CO6440584A2 (es)
CY (2) CY1119008T1 (es)
DK (3) DK2421849T3 (es)
ES (3) ES2417339T3 (es)
HK (1) HK1165799A1 (es)
HR (3) HRP20130468T1 (es)
HU (2) HUE042975T2 (es)
IL (1) IL215554A (es)
LT (2) LT3210981T (es)
MX (1) MX2011011156A (es)
MY (1) MY158339A (es)
NZ (1) NZ595850A (es)
PL (3) PL2421849T3 (es)
PT (3) PT3210981T (es)
RU (2) RU2543716C2 (es)
SG (1) SG175330A1 (es)
SI (3) SI3210981T1 (es)
SM (1) SMT201300060B (es)
TR (1) TR201903556T4 (es)
TW (2) TWI513693B (es)
WO (1) WO2010123766A1 (es)
ZA (1) ZA201107743B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3210981T1 (sl) 2009-04-23 2019-05-31 Theravance Respiratory Company, Llc Diamidne spojine, ki imajo muskarinsko receptorsko antagonistično in beta 2 adrenergično receptorsko agonistično aktivnost
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
AR083115A1 (es) 2010-09-30 2013-01-30 Theravance Inc Sales oxalato cristalinas de un compuesto diamida
KR101906630B1 (ko) 2011-06-10 2018-10-10 키에시 파르마슈티시 엣스. 피. 에이. 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
ES2552538T3 (es) 2011-06-10 2015-11-30 Chiesi Farmaceutici S.P.A. Compuestos que tienen una actividad antagonista de un receptor muscarínico y agonista de un receptor beta-2 adrenérgico
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EA030552B1 (ru) 2012-12-06 2018-08-31 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета2 адренергических рецепторов
CA2893627C (en) 2012-12-06 2021-09-14 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
US9518050B2 (en) 2012-12-18 2016-12-13 Almirall, S.A. Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
CN104030933A (zh) * 2014-05-16 2014-09-10 烟台恒迪克能源科技有限公司 一种β-异烷醇基氨基戊酸环己胺的合成方法
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
CN107074816B (zh) * 2015-03-27 2020-07-17 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
TW201704211A (zh) * 2015-05-14 2017-02-01 Sichuan Haisco Pharmaceutical Co Ltd 具有β２受體激動及Ｍ受體拮抗活性的聯苯衍生物及其在醫藥上的用途
WO2016180348A1 (zh) * 2015-05-14 2016-11-17 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
EP3383867B1 (en) 2015-12-03 2021-04-14 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
AU2017209340A1 (en) * 2016-01-22 2018-07-05 Sichuan Haisco Pharmaceutical Co., Ltd. Azacycle amide derivative, preparation method thereof, and pharmaceutical application
EP3484879B1 (en) 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CA3047023C (en) 2016-12-14 2022-05-31 Beijing Showby Pharmaceutical Co., Ltd. Class of bifunctional compounds with quaternary ammonium salt structure
US11065235B2 (en) 2017-05-19 2021-07-20 Council Of Scientific & Industrial Research Substituted methanopyrido [2, 1-a] isoindolones as mAChR modulators for treating various associated pathophysiological conditions and process for preparation thereof
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
WO2001042212A1 (en) 1999-12-07 2001-06-14 Theravance, Inc. Carbamate derivatives having muscarinic receptor antagonist activity
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
WO2002012265A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 6.ALPHA., 9.ALPHA.-DIFLUORO-17.ALPHA.-`(2-FURANYLCARBOXYL) OXY!-11.BETA.-HYDROXY-16.ALPHA.-METHYL-3-OXO-ANDROST-1,4,-DIENE-17-CARBOTHIOIC ACID S-FLUOROMETHYL ESTER AS AN ANTI-INFLAMMATORY AGENT
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
KR20040069319A (ko) * 2001-12-04 2004-08-05 가부시키 가이샤 도쿄 알 앤드 디 급전장치
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN101239971B (zh) * 2003-02-14 2011-07-20 施万制药 联苯衍生物
DK1708992T3 (da) 2004-01-22 2007-11-05 Pfizer Sulfonamidderivater til behandling af sygdomme
US7320990B2 (en) 2004-02-13 2008-01-22 Theravance, Inc. Crystalline form of a biphenyl compound
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7307076B2 (en) 2004-05-13 2007-12-11 Boehringer Ingelheim International Gmbh Beta agonists for the treatment of respiratory diseases
US7528253B2 (en) 2004-08-16 2009-05-05 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
DE602006014216D1 (de) 2006-02-08 2010-06-17 Fuji Oil Europe Esswaren mit einem niedrigen gehalt an gesättigten und trans-ungesättigten fetten
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
AU2009274567B2 (en) 2008-07-25 2013-04-04 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
SI3210981T1 (sl) 2009-04-23 2019-05-31 Theravance Respiratory Company, Llc Diamidne spojine, ki imajo muskarinsko receptorsko antagonistično in beta 2 adrenergično receptorsko agonistično aktivnost

Also Published As

Publication number Publication date
US20130331364A1 (en) 2013-12-12
CY1121601T1 (el) 2020-05-29
PL3210981T3 (pl) 2019-06-28
PT2421849E (pt) 2013-05-27
CA2758505A1 (en) 2010-10-28
US20200165223A1 (en) 2020-05-28
BRPI1014877A8 (pt) 2018-03-13
US20170096412A1 (en) 2017-04-06
US20150274697A1 (en) 2015-10-01
ES2715965T3 (es) 2019-06-07
EP2599778B1 (en) 2017-04-12
BRPI1014877B8 (pt) 2021-05-25
RU2015101032A3 (es) 2018-07-30
JP5671006B2 (ja) 2015-02-18
US8551978B2 (en) 2013-10-08
AR076412A1 (es) 2011-06-08
EP2421849B1 (en) 2013-04-03
BRPI1014877A2 (pt) 2016-04-12
CY1119008T1 (el) 2018-01-10
US10836744B2 (en) 2020-11-17
EP3210981B1 (en) 2019-01-02
US9682957B2 (en) 2017-06-20
US20170226082A1 (en) 2017-08-10
PT3210981T (pt) 2019-04-01
CN102405218A (zh) 2012-04-04
HRP20190417T1 (hr) 2019-04-19
US20130137665A1 (en) 2013-05-30
MY158339A (en) 2016-09-30
KR20110138292A (ko) 2011-12-26
DK2421849T3 (da) 2013-07-01
US8816088B2 (en) 2014-08-26
US9572802B2 (en) 2017-02-21
US9394275B2 (en) 2016-07-19
LT2599778T (lt) 2017-08-25
RU2676686C2 (ru) 2019-01-10
TW201041866A (en) 2010-12-01
PL2421849T3 (pl) 2013-08-30
IL215554A0 (en) 2011-12-29
IL215554A (en) 2014-08-31
US20170362200A1 (en) 2017-12-21
PL2599778T3 (pl) 2018-01-31
US10590107B2 (en) 2020-03-17
HUE042975T2 (hu) 2019-07-29
US10138220B1 (en) 2018-11-27
MX2011011156A (es) 2011-11-04
JP2015147807A (ja) 2015-08-20
HRP20170960T1 (hr) 2017-09-22
TWI513693B (zh) 2015-12-21
PT2599778T (pt) 2017-06-06
SI3210981T1 (sl) 2019-05-31
HK1165799A1 (en) 2012-10-12
US9975875B2 (en) 2018-05-22
LT3210981T (lt) 2019-04-10
US20100273755A1 (en) 2010-10-28
RU2543716C2 (ru) 2015-03-10
JP2012524783A (ja) 2012-10-18
HUE035049T2 (en) 2018-05-02
SI2599778T1 (sl) 2017-08-31
CN102405218B (zh) 2014-06-04
CN103936716B (zh) 2016-09-07
DK2599778T3 (en) 2017-06-26
AU2010239522A1 (en) 2011-11-10
JP5965440B2 (ja) 2016-08-03
US20160361304A1 (en) 2016-12-15
WO2010123766A1 (en) 2010-10-28
ES2635358T3 (es) 2017-10-03
EP2421849A1 (en) 2012-02-29
EP2599778A1 (en) 2013-06-05
JP2014210816A (ja) 2014-11-13
US8138345B2 (en) 2012-03-20
HRP20130468T1 (en) 2013-06-30
ES2417339T3 (es) 2013-08-07
RU2011147374A (ru) 2013-05-27
US10358433B2 (en) 2019-07-23
SMT201300060B (it) 2013-07-09
SI2421849T1 (sl) 2013-07-31
TWI570115B (zh) 2017-02-11
US9000173B2 (en) 2015-04-07
RU2015101032A (ru) 2015-06-27
US20190300504A1 (en) 2019-10-03
US20190047984A1 (en) 2019-02-14
US20140323733A1 (en) 2014-10-30
KR101769061B1 (ko) 2017-08-17
US9771350B2 (en) 2017-09-26
CN103936716A (zh) 2014-07-23
BRPI1014877B1 (pt) 2020-11-10
US20210024493A1 (en) 2021-01-28
DK3210981T3 (en) 2019-04-01
NZ595850A (en) 2013-05-31
SG175330A1 (en) 2011-11-28
TW201546057A (zh) 2015-12-16
CL2011002637A1 (es) 2012-04-27
ZA201107743B (en) 2012-06-27
CA2758505C (en) 2017-03-07
EP3210981A1 (en) 2017-08-30
AU2010239522B2 (en) 2015-07-02
TR201903556T4 (tr) 2019-04-22

Similar Documents

Publication Publication Date Title
CO6440584A2 (es) Compuestos diamida que tienen actividad como antagonistas de los receptores muscarínicos y como agonistas de los receptores adrenérgicos beta 2
PE20221914A1 (es) Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido
CO6741217A2 (es) Modulares de receptor de glucagón
EA201000024A1 (ru) Новые производные дикарбоновых кислот в качестве агонистов рецептора s1p1
EA201690033A3 (ru) Морфинановые соединения
CO6290683A2 (es) Compuestos de pirido imidazolinas heterociclicas y sus composiciones como inhibidores de c-met
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
PE20142285A1 (es) Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria
CO6321136A2 (es) Derivados de indazol sustituido por axadiazol para uso como agonistas de esfingosina 1 fosfato (s1p)
HN2010001563A (es) Compuestos
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
ECSP13012600A (es) CO-cristales y Sales de Inhibidores de CCR3
UY33278A (es) Pirimidinas sustituidas como antagonistas del receptor de la protaglandina d2
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
CO6361924A2 (es) Nuevas lactamas como inhibidores de beta secretasa
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
CO6300937A2 (es) Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu
UY33824A (es) ?moduladores del receptor del glucagón?.
CR11665A (es) Farmacoforos duales-antagonistas muscarinicos de pde4
AR080527A1 (es) Una pirimidina sustituida como un antagonista del receptor de la postaglandina d2
CL2009000236A1 (es) Compuestos derivados de triazolopiridazina, inhibidores de par1,procedimiento de preparacion y uso para profilaxis, prevencion y tratamiento de enfermedades asociadas con trombosis, embolia, hipercoagulabilidad, cambios fibroticos o trastornos inflamatorios.
CO6680604A2 (es) Forma cristalina de un compuesto 3-fenocimetilpirrolidina
CU20130106A7 (es) Moduladores del receptor de glucagón

Legal Events

Date Code Title Description
FG Application granted